Clinical and Translational Allergy最新文献

{"title":"Gamma Delta T Cells in Shrimp Allergy Express a Unique Cytotoxic Cytokine Profile","authors":"Brenda Bin Su,&nbsp;Tyler Jackson,&nbsp;Warren Blackmon,&nbsp;Harold Ames,&nbsp;Christopher Holt,&nbsp;Aikaterini Anagnostou,&nbsp;Vibha Szafron,&nbsp;Sara Anvari,&nbsp;Hongjie Li,&nbsp;Carla M. Davis","doi":"10.1002/clt2.70189","DOIUrl":"https://doi.org/10.1002/clt2.70189","url":null,"abstract":"<div>\u0000 \u0000 <p>Shellfish allergy is the most common food allergy in adults and the third most common in children. γδ T cells have been identified as playing a critical role in antigen tolerance in allergic diseases in mouse models. In humans, γδ T cells may play a regulatory role in peanut immunotherapy, and their role in shrimp allergy remains unclear. We hypothesized γδ T cells play a regulatory role in shrimp allergic disease. We performed single cell RNA sequencing (scRNAseq) on peripheral cells from shrimp allergic (SA) and healthy control (HC) subjects after stimulation with shrimp tropomyosin. This revealed a significant expansion of γδ T cells with three distinct clusters. One γδ T cell cluster predominated in SA, characterized as CD8+ with a cytotoxic expression profile. We found significant upregulation of TGF-β1 and downregulation of IL-7R in SA-stimulated γδ T cells, and IL-10RA expression in stimulated SA total PBMCs. γδ T cells may play a role in shrimp allergic disease through lymphocyte-mediated cytotoxin signaling and cytokine-mediated signaling pathways, including TGFβ-1, IL7/TSLP-IL7R, and IL10-IL10R pathways.</p>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 8","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paucigranulocytic Asthma in Aspirin-Hypersensitive Patients: Pleiotropic Regulation of Type 2 Biomarkers","authors":"Radosław Kacorzyk,&nbsp;Piotr Szatkowski,&nbsp;Agnieszka Gawlewicz-Mroczka,&nbsp;Adam Ćmiel,&nbsp;Anna Gielicz,&nbsp;Adam Stępień,&nbsp;Patryk Hartwich,&nbsp;Marek Sanak,&nbsp;Lucyna Mastalerz","doi":"10.1002/clt2.70186","DOIUrl":"10.1002/clt2.70186","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Up to 50% of patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) exhibit a noneosinophilic airway inflammatory phenotype, with paucigranulocytic asthma being the most prevalent. The aim was to identify clusters within N-ERD and aspirin-tolerant asthma (ATA) controls with a paucigranulocytic asthma phenotype.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Two separate hierarchical cluster analyses were performed using 23 variables in 36 N-ERD patients and 19 ATA controls. Variables included demographic, clinical, treatment-related, and hematologic parameters; sputum cytology; sinus computed tomography findings; and eicosanoid levels in induced sputum supernatant (ISS) and urine.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Two clusters were identified in each group: 1_N-ERD, 2_N-ERD, 1_ATA, and 2_ATA. Cluster 1_N-ERD patients had less severe asthma and required lower doses of inhaled corticosteroids (ICS) but showed higher blood eosinophil counts, Lund-Mackay (LM) scores, and ISS leukotriene E₄ (LTE₄) levels than those in cluster 2_N-ERD. Cut-off values defining a T2-high paucigranulocytic asthma profile in N-ERD included LM score ≥ 18, blood eosinophils ≥ 300 cells/mm³, and ISS LTE₄ ≥ 30 pg/mL, with the LM score demonstrating the highest AUC at 0.8. Among ATA controls, cluster 1_ATA had more severe asthma, higher ICS doses, more severe sinonasal disease, and increased ISS leukotriene D₄ and LTE₄ levels compared with cluster 2_ATA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Two clusters were identified among N-ERD patients with a paucigranulocytic asthma phenotype. Cluster 1_N-ERD was characterized by milder asthma, more severe sinonasal disease, elevated blood eosinophil counts, and elevated ISS LTE₄. This T2-high-like cluster may represent a subgroup requiring further evaluation for anti-T2 biologic therapy targeting chronic rhinosinusitis with nasal polyps, although further validation is required.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 7","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13381727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148520053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Between Guidelines and Daily Practice: The Persistent Use of Parenteral Depot Corticosteroids in Germany","authors":"Christian Taube,&nbsp;Timm Greulich,&nbsp;Sebastian Böing,&nbsp;Oliver Pfaar,&nbsp;Martin Wagenmann,&nbsp;Sven Becker,&nbsp;Mathias Sulk,&nbsp;Niklas J. Gerkau,&nbsp;Jan Claudius Schwitalla,&nbsp;Tim Vierbuchen","doi":"10.1002/clt2.70187","DOIUrl":"10.1002/clt2.70187","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Parenteral depot corticosteroids (PDCs) continue to be prescribed for allergic and respiratory diseases, despite clear guideline recommendations against their use. This clinical practice raises significant safety concerns. We analyzed current PDC use in Germany and characterized prescribing patterns.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Retrospective analysis of anonymized, longitudinal prescription data (IQVIA LRx) and evaluation of anonymized electronic medical record (EMR) data (IQVIA Disease Analyzer) from October 2023 to September 2024. Data were stratified by diagnosis, prescription frequency, prescriber specialty, region, age group and comorbidities.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The analysis of prescription data revealed that 9984 asthma and 5279 chronic obstructive pulmonary disease (COPD) patients received at least one PDC injection annually by general practitioners, which are the predominant prescribers. Of these patients, the majority received a single prescription. Regional differences were observed with particularly high prescription rates in western regions such as Rhineland-Palatinate and Saarland. Monthly PDC prescription rates follow seasonal patterns of most common pollen allergens. Furthermore, over 23,000 patients with rhinopathy but without asthma or COPD received at least one prescription as well as approximately 3700 patients with chronic sinusitis with or without nasal polyps but no asthma or COPD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>PDCs continue to be administered to a relevant number of patients with asthma, COPD, and upper airway diseases despite clear guideline recommendations against systemic steroid treatment. The injection frequency, as well as the association with allergic comorbidities and seasonal patterns are compatible with the treatment of seasonal allergies. This underscores the need for targeted educational initiatives and stronger implementation of guideline-adherent therapies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 7","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70187","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148419236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationships Between Bronchodilator Reversibility and Mannitol Airway Hyperresponsiveness in Severe Asthma","authors":"Philipp Suter,&nbsp;Robert Greig,&nbsp;Rory Chan,&nbsp;Brian J. Lipworth","doi":"10.1002/clt2.70188","DOIUrl":"10.1002/clt2.70188","url":null,"abstract":"&lt;p&gt;To the Editor,&lt;/p&gt;&lt;p&gt;Assessment of asthma includes symptom burden, exacerbation risk and functional evaluation. Functional assessment in asthma may include bronchodilator reversibility (BDR) and airway hyperresponsiveness (AHR). Although both are used to characterise variable airflow limitation, they reflect distinct underlying pathological mechanisms which are interlinked but may not necessarily align within individual patients [&lt;span&gt;1&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;BDR reflects the capacity of the airways, predominantly airway smooth muscle (ASM), to dilate in response to short-acting beta-agonists. Typically assessed by spirometry as the change in forced expiratory volume in 1 s (FEV&lt;sub&gt;1&lt;/sub&gt;). However, alternative methods, such as oscillometry, appear to be more sensitive to BDR than spirometry [&lt;span&gt;2&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;AHR can be assessed by either direct or indirect challenge tests. Mannitol acts as an indirect challenge, increasing periciliary liquid osmolarity to induce mast cell degranulation and synthesis of bronchoconstricting mediators, alongside eosinophil recruitment [&lt;span&gt;3&lt;/span&gt;]. Indirect challenges appear to relate more closely to eosinophilic airway inflammation and corticosteroid sensitivity than direct challenge testing [&lt;span&gt;4&lt;/span&gt;]. AHR is defined as the provocative dose of mannitol required to produce a pre-specified fall in FEV1, expressed on a log dose-response scale [&lt;span&gt;5&lt;/span&gt;]. A 10% fall (PD10) was used in the two analysed prospective studies, given all patients exhibited severe asthma. This cutoff was considered safer and more sensitive for this vulnerable population.&lt;/p&gt;&lt;p&gt;We undertook a post hoc analysis of a combined cohort of two clinical trials to evaluate the relationship between BDR and AHR [&lt;span&gt;5, 6&lt;/span&gt;]. To our knowledge, this is the first study to investigate this relationship specifically in patients with severe, uncontrolled asthma, using indirect bronchial challenge with mannitol.&lt;/p&gt;&lt;p&gt;We conducted a retrospective analysis of patients who demonstrated positive AHR defined as mannitol PD10 FEV1 of &lt; 635 mg, who underwent BDR to salbutamol 400 μg prior to starting biologics. Fractional exhaled nitric (FeNO) measurement (NIOX, Oxford, United Kingdom) followed by oscillometry (Thorasys Tremoflo, Montreal, Canada) and spirometry (Micromedical, Chatham, United Kingdom) were performed in accordance with European Respiratory Society guidelines. BDR was calculated as the difference between post and pre-bronchodilator measurements and relative change. Correlation analyses were assessed using Pearson's correlation coefficient with nominal two-tailed &lt;i&gt;p&lt;/i&gt; values reported as &lt; 0.05, &lt; 0.01, or &lt; 0.001. Statistical analyses were performed using SPSS version 30 (IBM Corp., Armonk, NY, USA).&lt;/p&gt;&lt;p&gt;We included 37 patients (16 females), with mean baseline values (SEM) as follows: age 51.9 years (2.4), body mass index 30.24 kg/m&lt;sup&gt;2&lt;/sup&gt; (0.84), eosinophils 512 cells/mL (43), FeNO 66.1 ppb (8.4), FE","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 7","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70188","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148396154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Real-World Cross-Sectional Study on Suspected Mast Cell Activation Syndrome: Multiple Heterogeneous Symptoms Identified","authors":"Annika Gutsche,&nbsp;Thomas Buttgereit,&nbsp;Rüdiger Buchkremer,&nbsp;Jens Panse,&nbsp;Nina Kreddig,&nbsp;Olga Ptock,&nbsp;Stephanie Roll,&nbsp;Weronika Grabowska,&nbsp;Felix Aulenbacher,&nbsp;Martin Metz,&nbsp;Polina Pyatilova,&nbsp;Pascale Salameh,&nbsp;Manuel P. Pereira,&nbsp;Frank Siebenhaar","doi":"10.1002/clt2.70184","DOIUrl":"10.1002/clt2.70184","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>A variety of clinical signs and symptoms have been described in patients suspected of having mast cell activation syndrome (MCAS), however, symptom patterns and linked organ systems were not yet described.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cross-sectional online survey included adults with physician-diagnosed self-assessed or suspected MCAS between June and September 2021. Symptoms were collected as free-text responses, and coded using the Medical Dictionary for Regulatory Activities (MedDRA). These data were then analyzed using an unsupervised machine learning approach to identify distinct participant clusters. Patient-reported outcome measures (PROMs), including the PHQ-2, GAD-7, and SF-36, were used to assess mental health symptoms and health-related quality of life.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 592 patients (mean age 45 years, 90% female) reported 400 symptoms in 58 categories. The hierarchical clustering algorithm failed to identify distinct patient clusters. We identified 256 (43%) patients with signs and symptoms aligning with the diagnostic criteria for MCAS including the most prevalent symptoms. Overall, patients infrequently reported mast cell-mediated skin symptoms, such as pruritus (13%), wheals (9%), flushing (7%), or angioedema (1%). We identified patients with comorbid signs of depression (39%), general anxiety (34%), and impaired quality of life (28%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Patients with suspicion of MCAS exhibit highly heterogeneous symptoms, whereas almost 50% report symptoms corresponding to the first diagnostic criterion for MCAS. Because over a third of the patients were tested positive for other diseases, we recommend considering common and more treatable diagnoses when evaluating patients with suspected MCAS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 7","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70184","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148381692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum and Nasal Lavage Fluid Eosinophil-Derived Neurotoxin Levels in Clinically Defined Asthma Phenotypes","authors":"Saliha Selin Özuygur Ermis,&nbsp;Carina Malmhäll,&nbsp;Magnus P. Borres,&nbsp;Robert Movérare,&nbsp;Daniil Lisik,&nbsp;Reshed Abohalaka,&nbsp;Selin Ercan,&nbsp;Susanne Schmeisser,&nbsp;Rani Basna,&nbsp;Roxana Mincheva,&nbsp;Göran Wennergren,&nbsp;Jan Lötvall,&nbsp;Linda Ekerljung,&nbsp;Madeleine Rådinger,&nbsp;Hannu Kankaanranta,&nbsp;Bright I. Nwaru","doi":"10.1002/clt2.70183","DOIUrl":"10.1002/clt2.70183","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>As a surrogate for eosinophilic activation, eosinophil-derived neurotoxin (EDN) is a potential clinical biomarker. However, EDN levels and discriminatory ability in different asthma phenotypes are unknown. We quantified serum and nasal lavage fluid (NLF) EDN levels and assessed the potential to differentiate clinically defined asthma phenotypes in an adult-representative sample.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 1499 serum and 386 NLF samples from individuals with current asthma obtained from the West Sweden Asthma Study were analyzed for EDN. Eosinophilic asthma was defined as blood eosinophil count of ≥ 300 cells/mm³, T2-high asthma was defined as blood eosinophil count of ≥ 300 cells/mm³ or fractional exhaled nitric oxide (FeNO) levels of ≥ 25 ppb. Other asthma phenotypes were defined based on presence of atopy, chronic rhinosinusitis (CRS), nasal polyposis, and obesity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Subjects with eosinophilic asthma had higher serum and NLF EDN levels than those with non-eosinophilic asthma. In ROC analyses, serum EDN provided excellent discrimination between eosinophilic and non-eosinophilic asthma (area under curve [AUC] = 0.84, 95% CI = 0.82–0.86); the corresponding AUC for NLF EDN was 0.67 (95% CI = 0.62–0.73). Serum and NLF EDN were higher in atopic asthma, T2-high asthma, and asthma with nasal polyposis compared to their counterparts, but not in asthma with CRS. The highest absolute values of serum and NLF EDN were observed in the high eosinophil + FeNO group, followed by the high-eosinophil-only and high-FeNO-only groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Both serum and NLF EDN were higher in those with eosinophilic compared to non-eosinophilic asthma. However, only serum EDN appears to distinguish eosinophilic asthma in ROC analyses.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 6","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70183","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148307179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allergen Immunotherapy for the Treatment of Eosinophilic Esophagitis. An EAACI Task Force Systematic Review","authors":"Martina Votto,&nbsp;Georgios Rentzos,&nbsp;Darío Antolin-Amerigo,&nbsp;Barbara Rymarczyk,&nbsp;George N. Konstantinou,&nbsp;Adam T. Fox,&nbsp;Antonella Cianferoni,&nbsp;Arzu Bakirtas,&nbsp;Carlo Maria Rossi,&nbsp;Marina Tsoumani,&nbsp;Enrico Heffler,&nbsp;Ingrid Terreehorst,&nbsp;Evangelia C. Apostolidou,&nbsp;Maria Beatrice Biló,&nbsp;Oliver Pfaar,&nbsp;Alfredo J. Lucendo,&nbsp;Georgios K. Nikolopoulos,&nbsp;Constantinos Pitsios","doi":"10.1002/clt2.70176","DOIUrl":"10.1002/clt2.70176","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Multiple routes of allergen immunotherapy (AIT) are approved for several IgE-mediated allergic diseases; however, the use of AIT in eosinophilic esophagitis (EoE) remains controversial and is supported by limited evidence. This review, conducted within the frame of an EAACI Task Force, aims to systematically evaluate the use of AIT as a potential treatment for EoE.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The protocol was registered and prepared in accordance with PRISMA guidelines. The literature search was conducted across three online databases (PubMed, Embase, and Scopus) and included studies published through January 31^st, 2025. Risk of Bias was assessed for each eligible study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Four articles met the inclusion criteria. Three articles evaluated EPIT for milk-induced EoE in pediatric patients, all from the SMILEE (Study of Efficacy and Safety of Viaskin Milk for milk-induced EoE) trial and its extensions. These included a randomized, placebo-controlled trial, its open-label extension, and a pilot immunological study. The SMILEE trial found no statistically significant difference in tissue eosinophilia between the active (EPIT) and control (placebo) arms in the intention-to-treat population, while 47% of treated EoE patients tolerated milk without recurrence of esophageal eosinophilia. This finding was further supported by a subsequent open-label study with a 2-year follow-up. In the third publication, the researchers found that EPIT was associated with decreased Th2-related transcripts and increased regulatory T-cell-associated transcripts. Only one eligible study evaluated the use of SCIT for treating EoE. It was a retrospective case-control study reporting that SCIT had a neutral effect and yielded inconclusive findings regarding the course of EoE.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>There is insufficient high-quality evidence to support the effectiveness of alternative routes of AIT for the treatment of EoE, either as an add-on or a standalone treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 6","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70176","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148276523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal Patterns of Allergen Sensitisation in the General Population: The LEAD Study","authors":"Charmaine J. M. Lim,&nbsp;Abdelrahman Omar,&nbsp;Severin Pötscher,&nbsp;Marie-Kathrin Breyer,&nbsp;Frits M. E. Franssen,&nbsp;Emiel F. M. Wouters,&nbsp;Robab Breyer-Kohansal","doi":"10.1002/clt2.70181","DOIUrl":"https://doi.org/10.1002/clt2.70181","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Allergic sensitisation is traditionally viewed as a stable trait despite studies suggesting that it may vary across life-course. This study aims to provide longitudinal evidence of allergic sensitisation and its associated factors in the general population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Aeroallergen sensitisation was assessed in the Austrian population-based cohort using repeated skin prick testing (SPT) across 3 visits (mean visit interval, 4.25 ± 0.33 years). Longitudinal sensitisation patterns were characterised as stable nonsensitised, stable sensitised, new-onset, resolution or fluctuating. We examined demographic, metabolic, behavioural, environmental and immunological factors across age strata (&lt; 18, 18 ≤ 40, 40 ≤ and ≥ 60 years).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 5046 individuals with follow-up and valid SPT in all 3 visits, 54.4% remained stably nonsensitised and 30.6% stably sensitised, 5.6% experienced resolution, 4.8% new onset and 4.6% fluctuating sensitisation. New onset expectedly predominated in &lt; 18 years, fluctuation in 18 ≤ 60 years and resolution in ≥ 60 years, indicating that sensitisation is modifiable and time-varying. Stable sensitisation was strongly associated with parental allergy and blood eosinophils while cumulative smoking modestly reduced its likelihood. Fluctuation was linked to adiposity (in adults ≥ 40 years old) and environmental exposures. Aeroallergen-specific analysis showed new-onset sensitisation was driven by outdoor allergens (ragweed, tree pollens and pets) whereas fluctuation was driven by seasonal pollens.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Although predominantly stable, allergic sensitisation is dynamic and exhibits substantial temporal variation. Resolution and fluctuation occur across all ages and new sensitisation can emerge well into adulthood. These findings challenge the traditional view of fixed sensitisation and suggest it reflects a modifiable phenotype shaped by age and environmental and lifestyle exposures.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 6","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70181","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148237818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unique Sensitization Patterns to Allergen Components in a Crustacean-Allergic Australian Cohort","authors":"Elecia Johnston,&nbsp;Sahel Heidari,&nbsp;Shaymaviswanathan Karnaneedi,&nbsp;Diamond Hira,&nbsp;Sandip Kamath,&nbsp;Andreas Ludwig Lopata","doi":"10.1002/clt2.70120","DOIUrl":"10.1002/clt2.70120","url":null,"abstract":"&lt;p&gt;Crustacean allergy affects 1%–3% of the global population, with shrimp being a common trigger. Tropomyosin (TM) is reported to be the primary allergen in up to 80% of cases, but other allergens such as arginine kinase (AK), myosin light chain (MLC), and haemocyanin may also contribute to allergic reactions. Despite the widespread prevalence of crustacean allergies, the diagnostic accuracy of whole extracts versus single components remains underexplored in Oceania [&lt;span&gt;1-4&lt;/span&gt;]. This is particularly important given the variety of crustacean species, including crabs and lobsters, each containing allergens that may differ in sequence homology and in their relative abundance across species.&lt;/p&gt;&lt;p&gt;This study reports allergic sensitisation patterns in 54 individuals with confirmed crustacean allergy (Supporting Information S1: Table S1), who exhibited clinical symptoms and tested positive in skin prick tests (SPT) and/or ImmunoCAP assays (Table 1). Specific IgE sensitisation was assessed using the ALEX2 multiplex IgE test (Macro Array Diagnostics), which includes four crustacean whole extracts: shrimp mix (&lt;i&gt;Litopenaeus setiferus&lt;/i&gt;, &lt;i&gt;Farfantepenaeus aztecus&lt;/i&gt;, &lt;i&gt;Farfantepenaeus duorarum&lt;/i&gt;), &lt;i&gt;Pandalus borealis&lt;/i&gt; (Pan b), &lt;i&gt;Chionoecetes&lt;/i&gt; spp. (Chi spp.), and &lt;i&gt;Homarus gammarus&lt;/i&gt; (Hom g), along with five single allergen components: Pen m 1, Pen m 2, Pen m 3, Pen m 4, and Cra c 6. Subjects testing negative to all crustacean allergens on the array were further analysed using immunoblotting against &lt;i&gt;Penaeus monodon&lt;/i&gt; extract and purified haemocyanin, a shrimp species widely consumed in Australia and globally. Details of the protocol are provided in the Supplementary Methods.&lt;/p&gt;&lt;p&gt;The subjects displayed a wide array of IgE binding patterns, highlighting the complex nature of sensitization within this population. TM sensitisation was demonstrated in 40.7% of the cohort, followed by troponin C (TnC) (26%), AK (22%), sarcoplasmic calcium-binding protein (SCP) (13%), and MLC (4%) (Table 1; Supporting Information S1: Figure S1A). Notably, 45% did not show any binding to TM, which is generally considered to be the major allergen in crustacean allergy. Among these TM-negative subjects, 53.1% were instead sensitised to other allergens. Importantly, while 20% of the cohort were sensitised to multiple allergens, the majority (52%) were monosensitized to one of the five allergens tested, with the highest binding observed for TnC, followed by AK, SCP, and MLC (Table 1, Supporting Information S1: Figure S1B). Similar high reactivity to TnC was also observed in other studies from tropical regions in Hong Kong and Thailand [&lt;span&gt;5&lt;/span&gt;]. IgE levels against &lt;i&gt;P. monodon&lt;/i&gt; TM (Pen m 1) showed strong correlations with TMs from &lt;i&gt;Anisakis simplex&lt;/i&gt; (Ani s 3), &lt;i&gt;Dermatophagoides pteronyssinus&lt;/i&gt; (Der p 10), &lt;i&gt;Blomia tropicalis&lt;/i&gt; (Blo t 10), and &lt;i&gt;Periplaneta americana&lt;/i&gt; (Per a 7), with &lt;i&gt;R&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; values ranging from 0.","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 6","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70120","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148216717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin Tape Stripping: A Non-Invasive Approach Linking Epidermal Changes and Systemic Inflammation in Atopic Dermatitis","authors":"Ziyuan Tian,&nbsp;Ke Xue,&nbsp;Yong Cui","doi":"10.1002/clt2.70179","DOIUrl":"10.1002/clt2.70179","url":null,"abstract":"<p>Atopic dermatitis (AD) is a complex chronic inflammatory skin disease driven by skin barrier dysfunction, immune dysregulation, and microbial imbalance. Traditional sampling methods, such as biopsies and blood collection, have provided valuable pathophysiological insights. However, their invasiveness, associated discomfort, and limitations for repeated sampling have constrained a dynamic understanding of disease progression and treatment responses. In recent years, skin tape stripping (STS) has emerged as a minimally invasive or even non-invasive technique that addresses these limitations. STS enables the collection of corneocytes and upper granular layer cells from the epidermis, and when combined with high-throughput multi-omics technologies, such as RNA sequencing, proteomics, lipidomics, and metatranscriptomics, it provides a powerful platform to dissect the molecular mechanisms of AD, identify novel biomarkers, and facilitate stratification in precision medicine approaches.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 6","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70179","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148197550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}